HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025, is central to these efforts.
The limited commercial launch marks a critical step in HeartBeam's strategy to bring its cable-free, portable device to market. Unlike traditional ECG devices, HeartBeam's platform collects signals from three non-coplanar directions and synthesizes them into a 12-lead ECG, potentially enabling physicians to detect cardiac issues outside medical facilities. The company holds over 20 issued patents related to its technology. Investors and analysts will be watching for updates on adoption rates and feedback from early users.
Extended-wear patch development is another focal point, as HeartBeam aims to offer longer-term monitoring options for patients with intermittent or hard-to-capture arrhythmias. The AI programs mentioned could enhance diagnostic accuracy and speed, differentiating HeartBeam's offerings in the competitive cardiac monitoring market. The company's heart attack detection capabilities are also under development, which could address a significant unmet need for timely diagnosis.
The conference call details and a full press release are available at https://ibn.fm/yN939. HeartBeam's newsroom can be accessed at https://ibn.fm/BEAT for the latest updates. The company's forward-looking statements are subject to risks outlined in its SEC filings, including its Annual Report on Form 10-K and subsequent reports.
The Q1 2026 results will provide a financial snapshot of HeartBeam's progress amid its transition from development to commercialization. With FDA clearances in hand and a limited launch underway, the company is positioning itself to redefine cardiac health management by enabling actionable heart intelligence wherever the patient is. The upcoming call will be a key event for stakeholders to gauge momentum and strategic direction.
For more information on the terms of use and disclaimers, visit http://IBN.fm/Disclaimer.
